"Patients are always involved: we have already had similar experiences and we have seen that, after cases such as that of the Nas investigation in Florence", which highlighted alleged offenses relating to drug prescriptions, "there were then problems for the prescription of medicines, because the doctors were afraid of ending up in the crosshairs". Word of Rosaria Iardino, president of 'Donneinrete', who, presenting an information campaign on rheumatoid arthritis in Rome, spoke of the scandal involving the world of dermatology. "The responsibility - added Iardino - also belongs to those who fail to isolate 'not very respectable' people, who put their current account or their power at the center. Companies have not yet understood that this system does not pay, not only in terms of money, but also in terms of performance on the stock exchange, given that the companies involved in the Florence scandal are mostly listed. Clearly not all are like this and often without the industry, information campaigns could not be carried out. But doctors, as well as patient associations, must isolate who is corrupt".
Second Pier Carlo Sarzi Puttini, director of the rheumatology unit of the Sacco hospital in Milan, it was "excessive to put the arrest of a colleague on the front page, also because it seems that the resources obtained have been used for scholarships and to pay trainees, therefore for positive purposes. On the other hand, in Italy many specialist centers could not remain open without underpaid or unemployed doctors". My colleague Gabriele Valentini, director of the Rheumatology Unit at the II University of Naples, disagrees, according to whom, "even if something positive has been done, in good or bad faith, in parallel sentences have appeared describing '800 patients in parking lots'. Support from industries should only be accepted if 'unrestricted', i.e. without constraints. And in favor of diagnostic-prescriptive appropriateness, the Italian Rheumatology Society has already proposed in the past to carry out a check on how they are used biopharmaceuticals".
